Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $27.00

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.00.

A number of research firms recently weighed in on OLMA. JPMorgan Chase & Co. decreased their target price on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, November 13th. Finally, Oppenheimer restated an “outperform” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OLMA. Conway Capital Management Inc. acquired a new position in shares of Olema Pharmaceuticals in the 3rd quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. grew its position in Olema Pharmaceuticals by 67.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after acquiring an additional 4,442 shares during the period. Portland Investment Counsel Inc. bought a new stake in Olema Pharmaceuticals in the third quarter valued at $143,000. Cubist Systematic Strategies LLC acquired a new position in Olema Pharmaceuticals during the second quarter worth $145,000. Finally, SG Americas Securities LLC bought a new position in shares of Olema Pharmaceuticals during the third quarter valued at $156,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $10.12 on Wednesday. The company’s fifty day moving average is $11.30 and its two-hundred day moving average is $11.90. Olema Pharmaceuticals has a 52-week low of $7.68 and a 52-week high of $16.77. The firm has a market capitalization of $579.86 million, a price-to-earnings ratio of -4.62 and a beta of 2.02.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.